Non-squamous non-small cell lung cancer
Conditions
Interventions
docetaxel plus bevacizumab
Sponsors
Oita University Faculty of Medicine, Department of Medical Oncology & Hematology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)pathologically or cytologically confirmed non-squamous non-small lung cancer 2)patients with clinical stage IIIb/IV or recurrent post-operative status, unsuitable for curative therapy or recurrent 3)no prior chemotherapy 4)patients who have the measurable disease defined by RECIST v1.1 5)patients with ECOG PS 0-2 6)age 20 years or older 7)medically unfit for platinum-doublet chemotherapy 8)adequate organ functions 9)estimated survival of at least 3 months 10)with written informed consent
Exclusion criteria
Exclusion criteria: 1) with uncontrollable co-morbidities 2)with episode of hemoptysis 3)clinically unfit for bevacizumab containing chemotherapy 4)with severe allergy of the medication 5)with ineligible conditions judged by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Countries
Japan
Contacts
Public ContactMorinaga Ryotaro
Oita University Hospital Department of Medical Oncology
Outcome results
None listed